Allovectin-7: Difference between revisions
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
No edit summary |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | ==Overview== |
Revision as of 14:27, 14 August 2015
WikiDoc Resources for Allovectin-7 |
Articles |
---|
Most recent articles on Allovectin-7 Most cited articles on Allovectin-7 |
Media |
Powerpoint slides on Allovectin-7 |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Allovectin-7 at Clinical Trials.gov Clinical Trials on Allovectin-7 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Allovectin-7
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Allovectin-7 Discussion groups on Allovectin-7 Patient Handouts on Allovectin-7 Directions to Hospitals Treating Allovectin-7 Risk calculators and risk factors for Allovectin-7
|
Healthcare Provider Resources |
Causes & Risk Factors for Allovectin-7 |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Allovectin-7 is a substance that is being studied as a gene therapy agent in the treatment of cancer, such as malignant melanoma. It increases the ability of the immune system to recognize cancer cells and kill them.
External links
- Allovectin-7 entry in the public domain NCI Dictionary of Cancer Terms